These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21561320)

  • 21. Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours.
    Bae SK; Lee SJ; Kim JW; Kim YH; Kim SG; Lee MG
    Biopharm Drug Dispos; 2005 Mar; 26(2):77-83. PubMed ID: 15617135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
    Loos WJ; Baker SD; Verweij J; Boonstra JG; Sparreboom A
    Clin Pharmacol Ther; 2003 Oct; 74(4):364-71. PubMed ID: 14534523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative protein binding of taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin, in human plasma in vitro.
    Kim TK; Yoo HH; Kim EJ; Sa JH; Lee BY; Park JH
    Pharmazie; 2012 Sep; 67(9):789-91. PubMed ID: 23016452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats.
    Yoon I; Han S; Choi YH; Kang HE; Cho HJ; Kim JS; Shim CK; Chung SJ; Chong S; Kim DD
    Xenobiotica; 2012 Nov; 42(11):1110-9. PubMed ID: 22747239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine.
    Bae SK; Lee SJ; Lee JY; Lee Y; Lee I; Kim SG; Lee MG
    Int J Pharm; 2004 May; 275(1-2):227-38. PubMed ID: 15081153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics.
    Qu G; Wu X; Yin L; Zhang C
    Biomed Pharmacother; 2012 Feb; 66(1):46-51. PubMed ID: 22264883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals.
    Li X; Du L; Wang C; Liu Y; Mei X; Jin Y
    Pharmazie; 2011 Jul; 66(7):479-83. PubMed ID: 21812321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
    Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
    Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preparation of docetaxel liposomes and their pharmacokinetics in rabbits].
    Huang HB; Liu T; Lin ZC; Zhong JT; Lin PL; Liu JY; Tan YY; Li S; Liao H; Xu YH
    Ai Zheng; 2007 Dec; 26(12):1287-91. PubMed ID: 18076788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
    Zamboni WC; Combest AJ; DeLoia JA; Edwards RP; Bridges AS; Zamboni BA; Walko CM; Yu AY; Krivak TC; Kelley JL
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1255-62. PubMed ID: 21437702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats.
    Worley DR; Hansen RJ; Wittenburg LA; Chubb LS; Gustafson DL
    Anticancer Res; 2016 Oct; 36(10):5071-5078. PubMed ID: 27798866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat.
    Hamdy DA; Brocks DR
    Xenobiotica; 2011 Feb; 41(2):137-43. PubMed ID: 21058917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus.
    Leal N; Calvo R; Agrad FZ; Lukas JC; de la Fuente L; Suarez E
    J Pharm Pharmacol; 2005 Mar; 57(3):317-25. PubMed ID: 15807987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.